This article published in today's WSJ provides an important support for a new paradigm in clinical development. Although there were significant shortcomings, which would be obvious to anyone familiar with drug development process, the table at the end of the story is self explanatory. It does not take a financial guru to see what the advantage will be if you manage to save so much time and money in the process as this trial achieved, while introducing proper scientific scrutiny. This is what Transparency Life Sciences is about.
http://online.wsj.com/article/SB10001424052748704489604576283010994997034.html?mod=djemHL_t
No comments:
Post a Comment